

Alberta Biosimilar Initiative

Reminder for prescribers—Prolia switching deadline of May 1, 2025

Under the Alberta Biosimilar Initiative, adult patients currently taking the originator biologic drug, Prolia, must switch to the biosimilar version of their molecule **before May 1, 2025**, to maintain coverage of that molecule through the Alberta government-sponsored drug plans.

Unless an exception has been granted for the originator biologic, **as of May 1, 2025, patients will only receive coverage for the biosimilar version of denosumab through Alberta's government-sponsored drug plans.**

Providers are encouraged to assist their patients in switching as early as possible to ensure there is sufficient time for discussions with patients and for your patients to enroll in a new patient support program, if needed.

At this time, patients are being provided with a letter reminding them of the **May 1, 2025** deadline and advising them to please contact their physician to discuss the biosimilar and develop a plan for switching.

If you have questions regarding the Biosimilar Initiative please visit the [Alberta Blue Cross health care professionals resource page](#) or contact us at 1-866-998-8480.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct-bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

